Rani Therapeutics Holdings, Inc.
RANI
Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics. The company develops the RaniPill capsule, a platform that is intended to replace subcutaneous or IV injection of biologics with oral dosing. Its product pipeline includes RT-101, an octreotide, which has completed Phase I clinical trial for the treatment of neuroendocā¦ read more
Healthcare
Biotechnology
5 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$0.77
Price-5.63%
-$0.05
1Y
Price
Market Cap
$50.564m
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow Margin-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow MarginRevenue
$3.169m
+16.7%
1y CAGR+5.6%
3y CAGR-20.8%
5y CAGREarnings
-$29.442m
+5.7%
1y CAGR+2.1%
3y CAGR-65.2%
5y CAGREPS
-$0.41
+24.8%
1y CAGR+14.0%
3y CAGR-40.7%
5y CAGRBook Value
$35.543m
$51.879m
Assets$16.336m
Liabilities$3.941m
DebtDebt to Assets
7.6%
-0.4x
Debt to EBITDAFree Cash Flow
-$17.114m
+22.3%
1y CAGR+15.1%
3y CAGR-0.5%
5y CAGRNo items found.
Press Releases
Statements and updates from the company